Advertisement Valeo Pharma enters into distribution deal with Questcor for Synacthen Depot in Canada - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Valeo Pharma enters into distribution deal with Questcor for Synacthen Depot in Canada

Specialty pharmaceutical firm Valeo Pharma has entered into an agreement with Questcor Pharmaceuticals, a subsidiary of Mallinckrodt, to distribute Synacthen Depot (cosyntropin zinc hydroxide injection) in Canada.

Currently, Questcor operates as the autoimmune and rare diseases business of Mallinckrodt Pharmaceuticals.

In Canada, Synacthen Depot is approved for therapeutic use in patients diagnosed with many difficult-to-treat rare diseases and as a diagnostic agent to screen patients presumed to have adrenocortical insufficiency.

Under the deal, Valeo will be responsible for all sales, marketing, regulatory and quality activities for the product in Canada.

Valeo Pharma president and founder Steve Saviuk said: "The agreement for Synacthen Depot represents a further step in Valeo Pharma’s strategic shift in therapeutic focus.

"Combined with the recent sale of our dermatology division, Valeo Pharma is positioned as a rapidly growing, full-service specialty pharmaceutical company focused on bringing new and orphan specialty pharmaceutical products to the Canadian market."

Mallinckrodt is focused on developing, manufacturing, marketing and distributing specialty pharmaceutical products and medical imaging agents.